Harry Kleanthous

5.9k total citations · 1 hit paper
57 papers, 3.7k citations indexed

About

Harry Kleanthous is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Harry Kleanthous has authored 57 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 23 papers in Infectious Diseases and 19 papers in Immunology. Recurrent topics in Harry Kleanthous's work include Helicobacter pylori-related gastroenterology studies (17 papers), Viral gastroenteritis research and epidemiology (13 papers) and Influenza Virus Research Studies (12 papers). Harry Kleanthous is often cited by papers focused on Helicobacter pylori-related gastroenterology studies (17 papers), Viral gastroenteritis research and epidemiology (13 papers) and Influenza Virus Research Studies (12 papers). Harry Kleanthous collaborates with scholars based in United States, France and United Kingdom. Harry Kleanthous's co-authors include Abraham M. Y. Nomura, Richard M. Peek, P.-H. Chyou, Martin J. Blaser, Timothy L. Cover, S. Tabaqchali, Christopher L. Clayton, David Morgan, Philip J. Coates and Thomas P. Monath and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Harry Kleanthous

57 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.

1995 1.4k citations Harry Kleanthous et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harry Kleanthous United States	28	2.3k	1.5k	736	735	705	57	3.7k
John G. Nedrud United States	32	2.1k 0.9×	2.5k 1.6×	967 1.3×	810 1.1×	922 1.3×	81	4.8k
A Labigne France	26	2.1k 0.9×	1.1k 0.7×	559 0.8×	854 1.2×	300 0.4×	41	3.4k
Armelle Ménard France	32	1.3k 0.6×	635 0.4×	389 0.5×	522 0.7×	464 0.7×	88	2.6k
T. Ulf Westblom United States	20	1.6k 0.7×	668 0.4×	356 0.5×	532 0.7×	454 0.6×	47	2.4k
Christophe Burucoa France	31	1.6k 0.7×	436 0.3×	413 0.6×	545 0.7×	519 0.7×	107	2.5k
H. C. Zanen Netherlands	34	1.5k 0.6×	676 0.4×	527 0.7×	373 0.5×	1.4k 1.9×	88	4.4k
Peter L. Gorelick United States	16	1.2k 0.5×	1.2k 0.8×	513 0.7×	438 0.6×	424 0.6×	18	2.7k
Inga‐Maria Frick Sweden	27	862 0.4×	1.0k 0.7×	647 0.9×	191 0.3×	348 0.5×	50	3.4k
Akira Nishizono Japan	28	894 0.4×	534 0.3×	941 1.3×	295 0.4×	803 1.1×	169	3.0k
F A el-Zaatari United States	30	1.2k 0.5×	464 0.3×	819 1.1×	535 0.7×	995 1.4×	51	2.4k

Countries citing papers authored by Harry Kleanthous

Since Specialization

Citations

This map shows the geographic impact of Harry Kleanthous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Kleanthous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Kleanthous more than expected).

Fields of papers citing papers by Harry Kleanthous

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Kleanthous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Kleanthous. The network helps show where Harry Kleanthous may publish in the future.

Co-authorship network of co-authors of Harry Kleanthous

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Kleanthous. A scholar is included among the top collaborators of Harry Kleanthous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Kleanthous. Harry Kleanthous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singh, Randhir, Raju S Rajmani, Harry Kleanthous, et al.. (2023). Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice. Pharmaceutics. 15(12). 2759–2759. 2 indexed citations

An, Yaling, Patrice Dubois, Yan Huang, et al.. (2023). Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™. Vaccine. 41(17). 2793–2803. 4 indexed citations

Boudreau, Carolyn M., John S. Burke, Ashraf S. Yousif, et al.. (2023). Antibody-mediated NK cell activation as a correlate of immunity against influenza infection. Nature Communications. 14(1). 5170–5170. 7 indexed citations

Rajmani, Raju S, Randhir Singh, M. Seetharama Bhat, et al.. (2023). Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants. npj Vaccines. 8(1). 161–161. 3 indexed citations

Boudreau, Carolyn M., John S. Burke, Matthew J. Gorman, et al.. (2023). Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination. Cell Reports Medicine. 4(3). 100975–100975. 5 indexed citations

Kumru, Ozan S., Jennifer J. Doering, Katherine Berman, et al.. (2023). Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018TM Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen. Vaccines. 11(6). 1030–1030. 6 indexed citations

Kumru, Ozan S., Kawaljit Kaur, John M. Hickey, et al.. (2023). Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD). Human Vaccines & Immunotherapeutics. 19(2). 2264594–2264594. 1 indexed citations

Smet, Anouk, João Paulo Portela Catani, Tine Ysenbaert, et al.. (2022). Antibodies directed towards neuraminidase restrict influenza virus replication in primary human bronchial epithelial cells. PLoS ONE. 17(1). e0262873–e0262873. 6 indexed citations

Kothe, Michael, Jianxin Zhang, E.O. Oloo, et al.. (2022). Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B. SHILAP Revista de lepidopterología. 4. 96–105. 2 indexed citations

10.

Fan, Chengcheng, Alexander A. Cohen, Miso Park, et al.. (2022). Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes. Immunity. 55(12). 2419–2435.e10. 22 indexed citations

11.

Kleanthous, Harry, Judith M. Silverman, Karen W. Makar, et al.. (2021). Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. npj Vaccines. 6(1). 128–128. 71 indexed citations

12.

Adamson, Penelope J., Jing Jing Wang, Natalie G. Anosova, et al.. (2019). Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies. Vaccine. 38(8). 2077–2087. 2 indexed citations

13.

Ross, Ted M., Joshua M. DiNapoli, Maryann Giel–Moloney, et al.. (2019). A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains. Vaccine. 37(17). 2369–2376. 22 indexed citations

14.

Giel–Moloney, Maryann, Alexander A. Rumyantsev, Fred R. David, et al.. (2017). A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector. Vaccine. 35(49). 6898–6904. 8 indexed citations

15.

Mundle, Sophia T., Michael Kishko, Rachel Groppo, et al.. (2016). Core bead chromatography for preparation of highly pure, infectious respiratory syncytial virus in the negative purification mode. Vaccine. 34(32). 3690–3696. 15 indexed citations

16.

Jeong, Kwang‐il, Peter Piepenhagen, Michael Kishko, et al.. (2015). CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner. PLoS ONE. 10(6). e0130517–e0130517. 85 indexed citations

17.

Mundle, Sophia T., Maryann Giel–Moloney, Harry Kleanthous, К. В. Пугачев, & Stephen F. Anderson. (2014). Preparation of pure, high titer, pseudoinfectious Flavivirus particles by hollow fiber tangential flow filtration and anion exchange chromatography. Vaccine. 33(35). 4255–4260. 8 indexed citations

18.

Mundle, Sophia T., Hector Lopez Hernandez, John Catalan, et al.. (2013). High-Purity Preparation of HSV-2 Vaccine Candidate ACAM529 Is Immunogenic and Efficacious In Vivo. PLoS ONE. 8(2). e57224–e57224. 30 indexed citations

19.

Lee, Cynthia, Kenneth F. Soike, Paul J. Giannasca, et al.. (1999). Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine. 17(23-24). 3072–3082. 48 indexed citations

20.

Kleanthous, Harry, Norman K. Fry, Henry R. Smith, Roy Gross, & B. Rowe. (1988). The use of sorbitol-MacConkey agar in conjunction with a specific antiserum for the detection of Vero cytotoxin-producing strains ofEscherichia coliO 157. Epidemiology and Infection. 101(2). 327–335. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact